<DOC>
	<DOCNO>NCT01123083</DOCNO>
	<brief_summary>DEFEND-2 Phase 3 confirmatory study Phase 3 DEFEND-1 study . The study objective find 8-day series otelixizumab infusion lead great improvement insulin secretion compare placebo . Insulin secretion assess use mixed meal-stimulated C-peptide . Subjects assign receive either otelixizumab placebo ratio 2:1 ( 2/3 otelixizumab , 1/3 placebo ) . These study agent administer addition insulin , diet , standard care treatment .</brief_summary>
	<brief_title>Trial Otelixizumab Adolescents Adults With Newly Diagnosed Type 1 Diabetes Mellitus ( Autoimmune ) : DEFEND-2</brief_title>
	<detailed_description>The following visit require : - Screening Visits : 2 3 appointment conduct determine eligibility . At 2 visit participant drink liquid meal blood test do post-meal period . Participants also require wear continuous glucose monitor short period time . - Dosing Visits : 8 outpatient visit consecutive day , last 2-4 hour . - Follow-up Visits : weekly first month , every 2 week 3 month , follow monthly visit 1 year . There 3 visit second year . - The total duration study 2 year . - Glucose test strip glucose monitor provide participant duration study . Frequent glycemic monitoring occur lab test blood glucose self-monitoring help facilitate tight glycemic control subject . Subjects ask intermittently record insulin dos use telephone web base system continuous glucose monitoring perform every 6 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Ages 1217 Diagnosis diabetes mellitus , consistent ADA criteria No 90 day diagnosis administration study compound Requires insulin type 1 diabetes mellitus , require insulin time diagnosis administration study compound . In Canada , use insulin time dose . Stimulated Cpeptide level great 0.20 nmol/L less equal 3.50 nmol/L Positive one autoantibodies typically associate T1DM : antibody glutamic acid decarboxylase ( anti‑GAD ) ; antibody protein tyrosine phosphataselike protein ( anti‑IA‑2 ) ; zinc transporter autoantibody ( ZNT8 ) ; insulin autoantibody ( IAA ) . A subject positive insulin autoantibody ( IAA ) negative autoantibody eligible subject use insulin le 7 day total . •Other , significant medical condition base study doctor 's evaluation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>new onset type 1 diabetes</keyword>
	<keyword>juvenile diabetes</keyword>
	<keyword>T1DM</keyword>
	<keyword>Type 1 diabetes</keyword>
</DOC>